MLAB Mesa Laboratories Inc.

Leader in Corporate Development and Strategy Joins Mesa Labs Board of Directors

Leader in Corporate Development and Strategy Joins Mesa Labs Board of Directors

LAKEWOOD, Colo., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) announced the appointment of Shiraz Ladiwala to its Board of Directors, effective October 28, 2021. Shiraz previously worked in leadership roles at Thermo Fisher Scientific and retired on August 31, 2021.

With Mr. Ladiwala’s appointment, the Mesa Laboratories, Inc. Board of Directors will be comprised of eight directors, six of whom are independent.

“Shiraz’s extensive experience building a world class life sciences company and his knowledge in corporate development and the Asia/ Pacific region will be instrumental to helping Mesa achieve its strategic objectives” said John Sullivan, Ph.D., Chairman of the Board of Directors, “We’ve intentionally sought to identify a qualified executive with a deep international background to bring a unique perspective to our company, and Shiraz’s expertise will help further Mesa’s development and our purpose to Protect the Vulnerable®.”

During his 24-year career with Thermo Fisher Scientific, Shiraz Ladiwala held various, progressive leadership roles in the areas of corporate strategy and development and business operations, including Senior Vice President of Strategy and Corporate Development and General Manager of Asia/ Pacific. He has significant corporate strategic development experience, extensive knowledge of the life sciences, bioproduction and diagnostics industries, and a background in international business operations. Mr. Ladiwala has a leadership style characterized by cultural adaptability, strong business acumen, and financial knowledge. He received a bachelor’s degree in commerce from the University of Bombay and a Master of Business Administration from the University of Michigan Ross School of Business.

About Mesa Laboratories, Inc.

Mesa is a global leader in the design and manufacturing of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.

For more information about the Company, please visit its website at 



CONTACT: Gary Owens; President and CEO, or John Sakys; CFO, both of Mesa Laboratories, Inc.,  
EN
29/10/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Mesa Laboratories Inc.

 PRESS RELEASE

Mesa Labs Announces Third Quarter Results

Mesa Labs Announces Third Quarter Results LAKEWOOD, Colo., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its third fiscal quarter (“3Q26”) ended December 31, 2025 (amounts in thousands). 3Q26 Financial Summary – (comparisons are versus the same year ago period Revenues increased 3.6%Non-GAAP organic and core organic revenues1 growth was 3.6% and 1.2%, respectivelyNon-GAAP organic revenues growth exclu...

 PRESS RELEASE

MESA LABS DECLARES QUARTERLY DIVIDEND

MESA LABS DECLARES QUARTERLY DIVIDEND LAKEWOOD, Colo., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 16, 2026, to shareholders of record at the close of business on February 28, 2026. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharm...

 PRESS RELEASE

Mesa Labs to Present at the 44th Annual J.P. Morgan Healthcare Confere...

Mesa Labs to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 LAKEWOOD, Colo., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced that Gary Owens, President and CEO, and John Sakys, CFO will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th, 2026. Management will participate in a Formal Presentation at 4:30 p.m. Pacific Time. A live webcast of the presentation will be accessi...

 PRESS RELEASE

Mesa Laboratories, Inc. to Announce Third Quarter Results on February ...

Mesa Laboratories, Inc. to Announce Third Quarter Results on February 3, 2026 LAKEWOOD, Colo., Dec. 03, 2025 (GLOBE NEWSWIRE) --  - Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2026 at approximately 8:00 A.M. Eastern Time (ET) on Tuesday, February 3, 2026. About Mesa LaboratoriesMesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and se...

 PRESS RELEASE

Mesa Laboratories, Inc. to Participate in Upcoming Investor Conference...

Mesa Laboratories, Inc. to Participate in Upcoming Investor Conferences LAKEWOOD, Colo., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced that Gary Owens, President and CEO, and John Sakys, CFO will be attending the following upcoming conferences: Raymond James Napa Valley Small Cap SymposiumFormat: 1x1 Meetings Date: Monday, November 17, 2025Jefferies London Healthcare Conference Format: Fireside chatDate: Thursday, November 20, 2025Time: 12:00 p.m. GMTWebcast: 8th Annual Evercore Healthcare ConferenceFormat: Fireside chat Date: Wednesday, Decemb...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch